DNAPrint's DNA Witness Test Featured by US News and World Report
2003-06-18 11:31 ET - News Release
SARASOTA, Fla., June 18 /PRNewswire-FirstCall/ -- DNAPrint Genomics, Inc. (BULLETIN BOARD: DNAP) (DNAPrint or the "Company") reports today that its proprietary DNAWitness 2.0 test is featured in the June 23, 2003 issue of US News and World Report. The full-page article (p. 50) is titled "Getting DNA to bear witness."
Last week, ABC's "PrimeTime Thursday" covered the test, which provided the break for the Multi-Agency Homicide Task Force in the Louisiana Serial Killer case. For that interview, the famous Patricia Cornwell interviewed DNAPrint's CSO Tony Frudakis, Ph.D. Previous to that, a New York Times article dubbed the application of the genomics test as a historical first for the field of forensics. Among the more recent coverage -- Genome News Network has recently published an online story on the test at www.genomenewsnetwork.org/main.shtml .
DNAWitness is the world's first forensic test to measure BioGeographical Ancestry (BGA) admixture within individuals. BGA is the heritable component of race and it is read from sites of the DNA called Ancestry Informative Markers (AIMs). DNAPrint believes that it is the first company to have mined the genome for the best Ancestry Informative Markers (AIMs). The development of DNAWitness was enabled by the recently completed human genome project and DNAWitness is the first commercial test of its kind ever developed.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The DNA Witness analysis is a direct result of focused research by the DNAP research and development team.
In addition, using proprietary human genome research methods, the Company develops pharma-predictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com/ .
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
BILD dir deine Meinung!
QADSAN
